AI-generated summary
The authors report a single-institution study of 25 breast cancer patients who received light-emitting diode photobiomodulation before radiotherapy, compared with a control group of 45 patients. Patients in the photobiomodulation group had less severe radiation dermatitis and less pain, and the authors conclude the therapy might reduce radiation-induced skin toxicity. The single-institution, non-randomized design limits the strength of these findings.
- Participants
- 70
- Who or what was studied
- Breast cancer patients receiving adjuvant 3D conformal radiotherapy after breast-conserving surgery, with 25 in the photobiomodulation group, 45 in the control group, and a matched group of 25 generated from the control group
- Limits stated in the abstract
- Single-institution study with a non-randomized control group and a propensity-matched subgroup, so confounding and selection bias cannot be excluded.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Visual analogue scale, Light-emitting diode, GRADE, Photobiomodulation therapy, Control group, Adverse event, Wound healing. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.